Name: J&J asks US regulators to OK its one-shot COVID-19 vaccine
Brand: apnews.com
SKU: apnews-com-929
Availability: OnlineOnly

critic

J&J asks US regulators to OK its one-shot COVID-19 vaccine

preview

AP NEWS https://apnews.com/article/coronavirus-pandemic-coronavirus-vaccine-0bbaa5693035bab95cf4ccf9c8d3b98fClick to copyhttps://apnews.com/article/coronavirus-pandemic-coronavirus-vaccine-0bbaa5693035bab95cf4ccf9c8d3b98fClick to copyRelated topicsJohnson &amp; Johnson asked U.S. regulators Thursday to clear the world’s first single-dose COVID-19 vaccine, an easier-to-use option that could boost scarce supplies. J&amp;J’s vaccine was safe and offered strong protection against moderate to severe COVID-19, according to from a massive international study. It didn’t appear quite as strong as two-dose competitors made by Pfizer and Moderna -- a finding that may be more perception than reality, given differences in how each was tested.But the Food and Drug Administration is asking its independent advisers to publicly debate all the data behind the single-dose shot -- just like its competitors were put under the microscope -- before it decides whether to green light a third vaccine option in the U.S. The panel will meet Feb. 26.ADVERTISEMENTDr. Peter Marks, FDA’s vaccine chief, has cautioned against making comparisons before the evidence is all in.“With so much need to get this pandemic under control, I think we can’t ignore any tool in the tool chest,” he told the American Medical Association last week. “We will have to do our best to try to make sure that we find the populations that benefit the most from each of these vaccines and deploy them in a very thoughtful manner.”WHAT THE NUMBERS SHOWOverall, the single-dose vaccine was 66% effective at preventing moderate to severe COVID-19, according to early findings from a study of 44,000 people in the U.S., Latin America and South Africa.But it was 85% protective against the most serious symptoms — and starting 28 days after their shot, researchers found no one who got the vaccine needed hospitalization or died.WEAKER BUT STILL FIGHTS MUTATING VIRUSThe one-dose option worked better in the U.S. — 72% effective against moderate to severe COVID-19 — compared with 66% in Latin America and 57% in South Africa, where a more contagious mutant virus is spreading.Scientists have been looking for real-world evidence about how vaccines work as the world races to stay ahead of the rapidly mutating virus, and welcomed the news that the J&amp;J option — while weaker — did still offer protection.OTHER OPTIONSIn large U.S. studies, two doses of the Pfizer and Moderna vaccines proved 95% protective against any symptomatic COVID-19. But those studies were finished before the record virus surges of recent months and the appearance of the worrisome mutants, meaning such testing might not turn out the same if repeated today.J&amp;J also is studying a two-dose version of its vaccine, but results won’t be available for several more months.THE SUPPLYJ&amp;J said it would have some vaccine ready to ship if the FDA allows emergency use of the shot, but it didn’t reveal how much. The pharmaceutical giant said it expects to supply 100 million doses to the U.S. by the end of June.It expects to file a similar application with European regulators soon.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

AP NEWS https://apnews.com/article/coronavirus-pandemic-coronavirus-vaccine-0bbaa5693035bab95cf4ccf9c8d3b98fClick to copyhttps://apnews.com/article/coronavirus-pandemic-coronavirus-vaccine-0bbaa5693035bab95cf4ccf9c8d3b98fClick to copyRelated topicsJohnson &amp; Johnson asked U.S. regulators Thursday to clear the world’s first single-dose COVID-19 vaccine, an easier-to-use option that could boost scarce supplies. J&amp;J’s vaccine was safe and offered strong protection against moderate to severe COVID-19, according to from a massive international study. It didn’t appear quite as strong as...

public

Lauran Neergaard

Advancing the power of facts, globally 🌎

apnews.com

Credible

Speculation

Anecdotal Evidence

Generalization

Stacking the Deck

Appeal to Authority

Straw Man

Slippery Slope

Emotional Appeal

Red Herring

False Dilemma

Illogical

Moral Equivalency

Ad Hominem

Correlation w/o Causation

Semantics

Begging the Question

Faulty Analogy

Non Sequitur

Bandwagon

Dogmatism

Failing Occam's Razor

Biased

Pure Opinion

Hit Piece

Racial Bias

National Bias

Religious Bias

Financial Incentive

Political Agenda

Gender Bias

Misused Image/Video

Study Misinterpreted

Mistake

Misused Term

Science Misrepresented

Factual Error

Satire

Surface Level

Lack of Reliable Sources

Sensational

Not Credible

Investigative

Balanced

Well Sourced

Great Context

sports

entertainment

U.S.

international

business

technology

science

culture

politics

media

health

J&J asks US regulators to OK its one-shot COVID-19 vaccine

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS